The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

TKI Resistance in CML and Ponatinib for T315I Mutation

Sequential tyrosine kinase inhibitor strategies for resistant chronic myeloid leukemia

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is TKI Resistance in CML and Ponatinib for T315I Mutation?

BCR-ABL kinase domain mutations cause majority of TKI resistance with T315I gatekeeper mutation conferring resistance to imatinib, dasatinib, nilotinib and bosutinib.

Ponatinib designed to bind T315I-mutated BCR-ABL with substantial activity in pan-resistant disease.

Asciminib STAMP (specifically targeting the ABL myristoyl pocket) inhibitor binds outside ATP-binding site providing complementary mechanism.

Resistance mechanisms beyond kinase mutations include BCR-ABL overexpression, alternative signaling activation and BCR-ABL-independent leukemic clones.

Comprehensive mutational testing with Sanger sequencing or next-generation sequencing identifies specific mutations guiding therapy selection.

Symptoms

Loss of major molecular response or progression of leukemia despite continued TKI therapy indicates resistance.
Hematologic relapse with rising white blood count, splenomegaly and constitutional symptoms.
Accelerated phase or blast crisis transformation indicates aggressive disease progression.
Asymptomatic molecular relapse identified through BCR-ABL transcript monitoring guides early intervention.
TKI-related adverse events may necessitate dose modification or treatment switching.

Risk Factors

Suboptimal response to first-line therapy increases resistance development risk.
T315I mutation confers complete resistance to all approved TKIs except ponatinib and asciminib.
Compound mutations with multiple kinase domain alterations limit TKI options.
Cardiovascular risk factors influence ponatinib selection and dosing strategies.
Treatment adherence affects efficacy with poor adherence increasing resistance development.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Inadequate molecular response on first-line TKI warrants mutational testing and therapy switching consideration.
  • Loss of established molecular response or hematologic relapse requires urgent comprehensive evaluation.
  • T315I mutation identification mandates ponatinib or asciminib consideration with cardiovascular risk assessment.
  • Cardiovascular events on ponatinib including arterial occlusion require immediate evaluation and possible discontinuation.
  • Multidisciplinary management with hematology, cardiology and transplant team optimizes complex resistant CML cases.

Treatment Methods

01
Ponatinib starting dose 45 mg daily with potential reduction to 15 mg after major molecular response for vascular safety.
02
Asciminib 40 mg twice daily or 80 mg daily for chronic phase CML with T315I or other resistance mutations.
03
Sequential TKI selection based on resistance mutation profile and prior treatment exposures.
04
Allogeneic hematopoietic stem cell transplantation for blast phase, accelerated phase progression or refractory disease in eligible patients.
05
Comprehensive cardiovascular risk management including monitoring for arterial occlusive events with ponatinib, treatment of hypertension and hyperlipidemia, lifestyle modifications, regular molecular monitoring with BCR-ABL transcript quantification and proactive identification of resistance mutations optimize outcomes in this challenging clinical scenario.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.